Cargando…

Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis

BACKGROUND: Disparities exist regarding an efficient treatment for stroke. Polyarginines have shown promising neuroprotective properties based on available published studies. Thus, the present study aims to systemically review and analyze existing evidence regarding polyarginine's administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahmasbi, Fateme, Madani Neishaboori, Arian, Mardani, Mahta, Toloui, Amirmohammad, Komlakh, Khalil, Azizi, Yaser, Yousefifard, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847609/
https://www.ncbi.nlm.nih.gov/pubmed/36542540
http://dx.doi.org/10.1002/brb3.2858
_version_ 1784871495853408256
author Tahmasbi, Fateme
Madani Neishaboori, Arian
Mardani, Mahta
Toloui, Amirmohammad
Komlakh, Khalil
Azizi, Yaser
Yousefifard, Mahmoud
author_facet Tahmasbi, Fateme
Madani Neishaboori, Arian
Mardani, Mahta
Toloui, Amirmohammad
Komlakh, Khalil
Azizi, Yaser
Yousefifard, Mahmoud
author_sort Tahmasbi, Fateme
collection PubMed
description BACKGROUND: Disparities exist regarding an efficient treatment for stroke. Polyarginines have shown promising neuroprotective properties based on available published studies. Thus, the present study aims to systemically review and analyze existing evidence regarding polyarginine's administration efficacy in animal stroke models. METHOD: Medline, Scopus, Embase, and Web of Science were systematically searched, in addition to manual search. Inclusion criteria were administrating polyarginine peptides in stroke animal models. Exclusion criteria were previous polyarginine administration, lacking a control group, review articles, and case reports. Data were collected and analyzed using STATA 17.0; a pooled standardized mean difference (SMD) with a 95% confidence interval (CI), meta‐regression, and subgroup analyses were presented. Risk of bias, publication bias, and level of evidence were assessed using SYRCLE's tool, Egger's analysis, and Grading of Recommendations Assessment, Development and Evaluation framework, respectively. RESULTS: From the 468 searched articles, 11 articles were included. Analyses showed that R18 significantly decreases infarct size (SMD = –0.65; 95% CI: –1.01, –0.29) and brain edema (SMD = –1.90; 95% CI: –3.28, –0.51) and improves neurological outcome (SMD = 0.67; 95% CI: 0.44, 0.91) and functional status (SMD = 0.55; 95% CI: 0.26, 0.85) in stroke animal models. Moreover, R18D significantly decreases infarct size (SMD = –0.75; 95% CI: –1.17, –0.33) and improves neurological outcome (SMD = 0.46; 95% CI: 0.06, 0.86) and functional status (SMD = 0.35; 95% CI: 0.16, 0.54) in stroke models. CONCLUSION: Moderate level of evidence demonstrated that both R18 and R18D administration can significantly improve stroke outcomes in animal stroke models. However, considering the limitations, further pre‐clinical and clinical studies are warranted to substantiate the neuroprotective efficacy of polyarginines for stroke.
format Online
Article
Text
id pubmed-9847609
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98476092023-01-24 Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis Tahmasbi, Fateme Madani Neishaboori, Arian Mardani, Mahta Toloui, Amirmohammad Komlakh, Khalil Azizi, Yaser Yousefifard, Mahmoud Brain Behav Reviews BACKGROUND: Disparities exist regarding an efficient treatment for stroke. Polyarginines have shown promising neuroprotective properties based on available published studies. Thus, the present study aims to systemically review and analyze existing evidence regarding polyarginine's administration efficacy in animal stroke models. METHOD: Medline, Scopus, Embase, and Web of Science were systematically searched, in addition to manual search. Inclusion criteria were administrating polyarginine peptides in stroke animal models. Exclusion criteria were previous polyarginine administration, lacking a control group, review articles, and case reports. Data were collected and analyzed using STATA 17.0; a pooled standardized mean difference (SMD) with a 95% confidence interval (CI), meta‐regression, and subgroup analyses were presented. Risk of bias, publication bias, and level of evidence were assessed using SYRCLE's tool, Egger's analysis, and Grading of Recommendations Assessment, Development and Evaluation framework, respectively. RESULTS: From the 468 searched articles, 11 articles were included. Analyses showed that R18 significantly decreases infarct size (SMD = –0.65; 95% CI: –1.01, –0.29) and brain edema (SMD = –1.90; 95% CI: –3.28, –0.51) and improves neurological outcome (SMD = 0.67; 95% CI: 0.44, 0.91) and functional status (SMD = 0.55; 95% CI: 0.26, 0.85) in stroke animal models. Moreover, R18D significantly decreases infarct size (SMD = –0.75; 95% CI: –1.17, –0.33) and improves neurological outcome (SMD = 0.46; 95% CI: 0.06, 0.86) and functional status (SMD = 0.35; 95% CI: 0.16, 0.54) in stroke models. CONCLUSION: Moderate level of evidence demonstrated that both R18 and R18D administration can significantly improve stroke outcomes in animal stroke models. However, considering the limitations, further pre‐clinical and clinical studies are warranted to substantiate the neuroprotective efficacy of polyarginines for stroke. John Wiley and Sons Inc. 2022-12-21 /pmc/articles/PMC9847609/ /pubmed/36542540 http://dx.doi.org/10.1002/brb3.2858 Text en © 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Tahmasbi, Fateme
Madani Neishaboori, Arian
Mardani, Mahta
Toloui, Amirmohammad
Komlakh, Khalil
Azizi, Yaser
Yousefifard, Mahmoud
Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis
title Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis
title_full Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis
title_fullStr Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis
title_full_unstemmed Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis
title_short Efficacy of polyarginine peptides in the treatment of stroke: A systematic review and meta‐analysis
title_sort efficacy of polyarginine peptides in the treatment of stroke: a systematic review and meta‐analysis
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847609/
https://www.ncbi.nlm.nih.gov/pubmed/36542540
http://dx.doi.org/10.1002/brb3.2858
work_keys_str_mv AT tahmasbifateme efficacyofpolyargininepeptidesinthetreatmentofstrokeasystematicreviewandmetaanalysis
AT madanineishabooriarian efficacyofpolyargininepeptidesinthetreatmentofstrokeasystematicreviewandmetaanalysis
AT mardanimahta efficacyofpolyargininepeptidesinthetreatmentofstrokeasystematicreviewandmetaanalysis
AT tolouiamirmohammad efficacyofpolyargininepeptidesinthetreatmentofstrokeasystematicreviewandmetaanalysis
AT komlakhkhalil efficacyofpolyargininepeptidesinthetreatmentofstrokeasystematicreviewandmetaanalysis
AT aziziyaser efficacyofpolyargininepeptidesinthetreatmentofstrokeasystematicreviewandmetaanalysis
AT yousefifardmahmoud efficacyofpolyargininepeptidesinthetreatmentofstrokeasystematicreviewandmetaanalysis